Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
Go back to Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer| (NASDAQ: CUE) | Delayed: 1.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.60 | 52 Week High | $ | |||
| Open | $1.60 | 52 Week Low | $ | |||
| Day High | $1.60 | P/E | N/A | |||
| Day Low | $1.60 | EPS | $ | |||
| Volume | 63 | |||||
